Clinical Trials for adults with classic CAH

Spruce Bio is conducting two clinical trials evaluating its wholly-owned candidate, tildacerfont, a CRF₁ receptor antagonist, for the treatment of adults with classic congenital adrenal hyperplasia (CAH). Spruce is also conducting a Phase 2 trial in pediatric patients with classic CAH.

The CAHmelia clinical trials evaluating tildacerfont in adults with classic CAH have completed enrollment. To learn more, please visit sprucebio.com/cahmelia.

For more information on the ongoing trials in adult and pediatric patients with classic CAH, and in women with PCOS, please visit clinicaltrials.gov